As healthcare companies continue to refine and expand methods of achieving diversity, equity and inclusion, DE&I leaders know their efforts are not a sprint, but part of an ongoing journey.
Mylan NV reached a tentative agreement to pay $30 million to resolve a probe by the U.S. Securities and Exchange Commission related to the company’s emergency allergy shot EpiPen, which became the center of a firestorm over price increases.
